SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-23-023319
Filing Date
2023-08-11
Accepted
2023-08-11 16:06:00
Documents
70
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q navb20230630_10q.htm   iXBRL 10-Q 1301546
2 EXHIBIT 31.1 ex_555157.htm EX-31.1 8656
3 EXHIBIT 31.2 ex_555158.htm EX-31.2 8655
4 EXHIBIT 32.1 ex_555159.htm EX-32.1 4493
5 EXHIBIT 32.2 ex_555160.htm EX-32.2 4402
  Complete submission text file 0001437749-23-023319.txt   7337029

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA navb-20230630.xsd EX-101.SCH 71140
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20230630_def.xml EX-101.DEF 539453
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20230630_lab.xml EX-101.LAB 430252
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20230630_pre.xml EX-101.PRE 560821
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20230630_cal.xml EX-101.CAL 45218
64 EXTRACTED XBRL INSTANCE DOCUMENT navb20230630_10q_htm.xml XML 1011971
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 231164043
SIC: 2835 In Vitro & In Vivo Diagnostic Substances